CMC Project Lead (Next Generation Biologics and ADCs), London

Essential:

PhD or MSc in Biochemistry, Chemical Engineering, Chemistry, or a related biopharmaceutical field.

8+ years (or 5+ for high-growth) of professional experience in biologics CMC, with a proven track record of moving complex modalities from late-stage discovery into clinical manufacturing.

Experience with a diverse range of next-gen scaffolds, such as bispecific antibodies, nanobodies (VHH), or cytotoxic and non-cytotoxic/novel payload delivery systems.

Direct, hands-on experience in the development, scale-up, or manufacturing of Antibody-Drug Conjugates (ADCs) or other chemically modified biologics.

Deep knowledge of analytical techniques required for multi-component molecules, including Drug-to-Antibody Ratio (DAR) determination and advanced peptide mapping/MS-based characterization.

We are seeking a highly technical and collaborative Senior Chemistry, Manufacturing, and Controls Project Lead to drive the development and CMC strategy for our next-generation biologics and Antibody-Drug Conjugates (ADC) pipeline. This is a high impact position at the nexus of protein design and engineering, sophisticated linker-payload chemistry and complex regulatory sciences. The role requires a candidate who can navigate the unique challenges of multi-part drug substances and harmonise them into a stable, scalable therapeutic.

As the CMC Lead, you will serve as the technical expert for our diverse portfolio of computationally designed therapeutic candidates. This is a high-impact leadership role responsible for building the bridge between Isomorphic’s AI-driven discovery engine and the physical manufacturing of clinic-ready drugs.

You will design the CMC strategy for a variety of complex biologics and multi-specifics. You will oversee the end-to-end technical development, from cell line optimisation and sophisticated upstream/downstream processing to the precision chemistry required for advanced conjugation and assembly. We are looking for a visionary who thrives at the intersection of biology and chemistry, capable of navigating the unique CMC hurdles of next-generation modalities while ensuring a robust, scalable path to the clinic:

Design and oversee end-to-end manufacturing frameworks for a diverse portfolio of novel scaffolds and functionalized antibodies. This includes orchestrating cell line development, advanced upstream/downstream biologics processing, and the precision molecular assembly or conjugation steps required for next-generation therapeutic formats.

Lead the optimization of site-specific modification and coupling chemistries (e.g., conventional and novel conjugation). You will drive strategies to achieve precise stoichiometry (including Drug-to-Antibody Ratios) and structural homogeneity while minimizing product-related impurities and "off-target" modifications.

Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.

Our name comes from the belief that there is an underlying symmetry between biology and information science. By harnessing AI’s powerful capabilities, we can use it to model complex biological phenomena to help design novel molecules, anticipate how drugs will perform and develop innovative medicines to treat and cure some of the world’s most devastating diseases.

We have built a world-leading drug design engine comprising AI models that are capable of working across multiple therapeutic areas and drug modalities. We are continually innovating on model architecture and developing cutting-edge capabilities to advance rational drug design.

Every day, and with each new breakthrough, we’re getting closer to the promise of digital biology, and achieving our ambitious mission to one day solve all disease with the help of AI.